ARTICLE | Company News
PTAB rejects Bass' Imbruvica challenge
October 21, 2015 12:57 AM UTC
The Patent Trial and Appeals Board of the U.S. Patent and Trademark Office denied an inter partes review (IPR) petition from Kyle Bass' Coalition for Affordable Drugs challenging a patent covering Imbruvica ibrutinib from AbbVie Inc. (NYSE:ABBV).
The coalition had challenged U.S. Patent No. 8,754,090. The patent is one of 12 Orange Book-listed patents covering Imbruvica and expires June 3, 2031. ...